COMMUNIQUÉS West-GlobeNewswire

Health Canada has authorized TAKHZYRO(TM) (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks
20/09/2018
Health Canada has authorized TAKHZYRO TM (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks New treatment option for HAE receives first [...]
Santé Canada autorise TAKHZYRO(MC) (lanadelumab en injection), le premier traitement à anticorps monoclonal en son genre destiné à la prévention de crises d’angioœdème héréditaire (AOH)
20/09/2018
Santé Canada autorise TAKHZYRO MC (lanadelumab en injection), le premier traitement à anticorps monoclonal en son genre destiné à la prévention de crises d’angioœdème héréditaire (AOH) Une nouvelle option de traitement [...]
Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference
20/09/2018
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host [...]
RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
20/09/2018
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
Canada House Wellness Group Announces $25,000,000 Financing and Issuance of Stock Options
20/09/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE: CHV) (“ Canada House ” or the “ Company ”) is [...]
New TRU NIAGEN PRO Launched for Expansive Distribution by Healthcare Practitioners
20/09/2018
Addressing aging population, TRU NIAGEN PRO now available for distribution by healthcare practitioners for patient health and wellness IRVINE, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an [...]
HEXO soutient le programme d’information sur le cannabis de la Société gastro-intestinale
20/09/2018
GATINEAU, Québec, 20 sept. 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (« HEXO » ou la « Société ») (TSX: HEXO ) s’intéresse beaucoup à la responsabilité sociale d’entreprise (RSE) et à cet égard, elle examine attentivement l’ [...]
Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast’s Phase 3 Trial for Acute Graft Versus Host Disease
20/09/2018
Preparations for Biologics License Application (BLA) Filing Underway NEW YORK and MELBOURNE, Australia, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced continued strong [...]
Digirad Corporation to Present at the Sidoti & Company Fall 2018 Conference on September 27, 2018
20/09/2018
SUWANEE, Ga., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ:DRAD), today announced that it will present at the Sidoti & Company Fall 2018 Conference on Thursday, September 27, 2018, at the New York [...]
Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
20/09/2018
License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to [...]
Canopy Rivers Inc. Begins Trading on the TSX Venture Exchange
20/09/2018
TORONTO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (TSXV:RIV) (“ Canopy Rivers ” or the “ Company ”) is pleased to announce that effective at the opening of the market today, September 20, 2018, the Company’ [...]
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology
20/09/2018
BEIJING, China and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Photocure ASA: Daniel Schneider appointed Chief Executive Officer
20/09/2018
Oslo, Norway, 20 September 2018: Photocure ASA (OSE: PHO), announces today that Daniel Schneider has been appointed President and Chief Executive Officer of Photocure. Mr Schneider joins Photocure from the position of [...]
Solon Eiendom ASA – Primary insider notification
20/09/2018
(Oslo, Norway, September 19, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 20.000 shares in Solon Eiendom ASA at a price of NOK 28.9831. Following [...]
Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018
20/09/2018
Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 Strengthening of NBTXR3 data showing the potential impact on survival in elderly and frail patients [...]
Nanobiotix : mise à jour des données de l’étude de Phase I/II dans les cancers de la tête et du cou et autres données présentées à ImmunoRad 2018
20/09/2018
Nanobiotix : mise à jour des données de l’étude de Phase I/II dans les cancers de la tête et du cou et autres données présentées à ImmunoRad 2018 Renforcement des données de NBTXR3 montrant l’impact potentiel de survie [...]
Shire plc: Rule 2.9 Announcement
20/09/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 20 September 2018 [...]
Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences
20/09/2018
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be [...]
Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
20/09/2018
Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR), a biopharma company ( formerly known as ThromboGenics ) focused on developing treatments for back of the eye diseases with an innovative [...]

Pages